BMS and Pfizer announce new data for Eliquis (apixaban)
11 December 2015 | By Victoria White
In the data from the Phase 3 AMPLIFY study, Eliquis (apixaban) was comparable to conventional therapy in recurrent venous thromboembolism (VTE)...
List view / Grid view
News
NICE says ‘yes’ to heart failure drug sacubitril valsartan
11 December 2015 | By Victoria White
Sacubitril valsartan is an angiotensin receptor neprilysin inhibitor. Neprilysin inhibits the actions of peptides in dilating the blood vessels...
NICE changes decision on AstraZeneca’s olaparib
11 December 2015 | By Victoria White
NICE intends to recommend Lynparza (olaparib) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer after AstraZeneca provided more information on the drug...
New data for Eisai’s eribulin presented at SABCS
11 December 2015 | By Victoria White
New data supports the previously shown ability of Eisai’s Halaven (eribulin) to reverse epithelial-to-mesenchymal transition...
NICE recommends enzalutamide; consults on abiraterone
11 December 2015 | By Victoria White
The National Institute for Health and Care Excellence (NICE) has published draft guidance on two prostate cancer treatments - enzalutamide and abiraterone...
Oxygen-enhanced MRI detects hypoxia within tumours
10 December 2015 | By Victoria White
Teams at The University of Manchester and The Institute of Cancer Research, London, have described detailed development of oxygen-enhanced magnetic resonance imaging (MRI) technology to map areas of oxygen deprivation within tumours.
Immunology treatment market to expand to $74.2b by 2022
10 December 2015 | By Victoria White
According to business intelligence provider GBI Research, the global immunology treatment market is set to expand from $61.5 billion in 2015 to reach $74.2 billion in 2022...
PSL support Singapore increasing pharmaceutical manufacturing
10 December 2015 | By PSL
Powder Systems Limited (PSL), an international award-winning manufacturer of filtration, drying and high containment isolators for the pharmaceutical and biopharmaceutical industries, recently delivered several advanced process installations in Singapore...
Lilly and Merck expand their immuno-oncology collaboration
10 December 2015 | By Victoria White
The companies are to evaluate Lilly’s abemaciclib (LY2835219) and Merck’s Keytruda (pembrolizumab) in a Phase I study across multiple tumour types...
cFDA announces big regulatory policy changes in China
10 December 2015 | By Victoria White
According to PaizaBio, a company focused on helping Western-based pharmaceutical companies manufacture drugs in China for the Chinese market, the new policies will impact both Chinese and Western pharmaceutical companies...
Novo Nordisk submits NDA for faster-acting insulin aspart
10 December 2015 | By Victoria White
Faster-acting insulin aspar is an investigational mealtime insulin developed by Novo Nordisk for the control of blood sugar levels in adults with type 1 and type 2 diabetes...
FDA approves Vonvendi for the treatment of von Willebrand Disease
9 December 2015 | By Victoria White
Vonvendi [von Willebrand factor (Recombinant)] is the first and only recombinant treatment for adults living with von Willebrand Disease (VWD)...
FDA approves Alexion’s Kanuma for LAL deficiency
9 December 2015 | By Victoria White
Kanuma (sebelipase alfa) has been approved for the treatment of patients with a diagnosis of lysosomal acid lipase deficiency (LAL-D)...
AML treatment market to reach $932.6 million by 2024
9 December 2015 | By Victoria White
The treatment market for acute myeloid leukaemia (AML) will rapidly expand in value from $342.7 million in 2014 to reach $932.6 million by 2024, says research and consulting firm GlobalData.
Repurposed ebselen shows promise in bipolar trial
9 December 2015 | By Victoria White
In a small trial, where healthy adult volunteers were given a course of ebselen, the results showed that ebselen had similar effects on the brain to lithium...
